Use of ouabain antagonists to inhibit viral infection

Abstract

Embodiments of a method for inhibiting viral infection in a subject are provided herein. In some embodiments, the method comprises administration of a competitive antagonist of ouabain binding to ATP1A1 to inhibit respiratory syncytial virus infection in the subject.

It is claimed: 
     
         1 . A method of inhibiting a viral infection in a subject, comprising administering a therapeutically effective amount of an agent to the subject to inhibit the viral infection, wherein the agent is a competitive antagonist of ouabain binding to ATP1A1. 
     
     
         2 . The method of  claim 1 , wherein the agent is a small molecule competitive antagonist of ouabain binding to ATP1A1. 
     
     
         3 . The method of  claim 1 , wherein the agent is PST2238. 
     
     
         4 . The method of  claim 1 , wherein the viral infection is an infection with a negative-sense single-stranded RNA virus. 
     
     
         5 . The method of  claim 1 , wherein the viral infection is an infection with virus of the Pneumoviridae family. 
     
     
         6 . The method of  claim 1 , wherein the viral infection is an infection with a virus that utilizes epidermal growth factor receptor signaling for cellular entry. 
     
     
         7 . The method of  claim 6 , wherein the virus is any one of: Respiratory Syncytial Virus, Adenovirus, Clade A New World arenavirus Pichindé, African swine fever virus, Hepatitis C virus, Hepatitis B virus, Human cytomegalovirus, Herpes simplex virus, Epstein-Barr virus, Influenza A virus, Human papillomavirus, Human parainfluenza virus Type 1-3, Adeno-associated virus, Enterovirus 71, Rhinovirus, Vaccinia virus, Cowpox virus, Western Reserve, International Health Department-J, Shope fibroma virus, Human immunodeficiency virus, Avian erythroblastosis virus, Mouse Cas NS-1 retrovirus 
     
     
         8 . The method of  claim 7 , wherein the virus is the Respiratory Syncytial Virus. 
     
     
         9 . The method of  claim 1 , wherein the viral infection is an infection with a virus that utilizes ATP1A1 signaling for cellular entry. 
     
     
         10 . The method of  claim 9 , wherein the viral infection is an infection with any one of influenza virus, Herpes simplex virus, Chikungunya virus, Human immunodeficiency virus type 1, Adenovirus, Porcine reproductive, respiratory syndrome virus 1, Ebola virus, Coronavirus, Hepatitis C virus, Lymphocytic choriomeningitis virus, Lassa virus, or Junin virus. 
     
     
         11 . The method of  claim 1 , wherein the agent is administered to the subject by oral, intranasal, inhalation, intramuscular, intravenous, peritoneal, or subcutaneous administration. 
     
     
         12 . The method of  claim 11 , wherein the agent is administered intranasally to the subject. 
     
     
         13 . The method of  claim 11 , wherein the agent is administered to the subject with a nebulizer. 
     
     
         14 . The method of  claim 1 , wherein the subject has or is at risk of the viral infection. 
     
     
         15 . The method of  claim 14 , wherein the subject has the viral infection and the method treats the viral infection in the subject. 
     
     
         16 . The method of  claim 14 , wherein the subject is at risk of the viral infection and the method prevents the viral infection in the subject or reduces the severity of symptoms of the viral infection if the subject subsequently becomes infected. 
     
     
         17 . The method of  claim 1 , further comprising selecting a subject with or at risk of the viral infection for administration of the agent. 
     
     
         18 . A method of inhibiting a Respiratory Syncytial Virus infection in a subject comprising administering to the subject a therapeutically effective amount of PST2238.